Skip to main content
Fig. 1 | Diabetology & Metabolic Syndrome

Fig. 1

From: Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus

Fig. 1

Luseogliflozin improved elevated glucose concentrations and normalized HFDT feeding-induced hepatosteatosis. a Control, NA/STZ/HFDT and NA/STZ/HFDT/Luseo mice. b, c Blood glucose and insulin concentrations in fasted states. d Whole body and liver weights. e Serum ALT level. f Serum triglyceride, cholesterol and non-esterified fatty acids (NEFA) levels. All data are shown as means + SEM

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us